𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

✍ Scribed by RC Coombes; LS Kilburn; CF Snowdon; R Paridaens; RE Coleman; SE Jones; J Jassem; CJH Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; AS Coates; E Bajetta; SB Holmberg; D Dodwell; E Mickiewicz; J Andersen; PE Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; LJ Fallowfield; G Bertelli; E Hall; RG Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; JM Bliss

Book ID
117300630
Publisher
The Lancet
Year
2007
Tongue
English
Weight
314 KB
Volume
369
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival and safety of exemestane versus
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
✍ RC Coombes; LS Kilburn; CF Snowdon; R Paridaens; RE Coleman; SE Jones; J Jassem; 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 314 KB

## Background: Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer. however, little information exists on the long-term effects

Switching to exemestane after 2–3 years
Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen: Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.
✍ Christina Davies 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 248 KB